MX2018006155A - A solid state form of pladienolide pyridine compounds and methods of use. - Google Patents
A solid state form of pladienolide pyridine compounds and methods of use.Info
- Publication number
- MX2018006155A MX2018006155A MX2018006155A MX2018006155A MX2018006155A MX 2018006155 A MX2018006155 A MX 2018006155A MX 2018006155 A MX2018006155 A MX 2018006155A MX 2018006155 A MX2018006155 A MX 2018006155A MX 2018006155 A MX2018006155 A MX 2018006155A
- Authority
- MX
- Mexico
- Prior art keywords
- solid state
- state form
- pyridine compounds
- methods
- pladienolide pyridine
- Prior art date
Links
- 239000007787 solid Substances 0.000 title abstract 4
- 150000003222 pyridines Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 210000001324 spliceosome Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The present disclosure provides a novel solid state form of pladienolide pyridine compounds, compositions comprising at least one such solid state form, and methods of preparation and use and the same. The novel solid state form of pladienolide pyridine compounds may be useful in the treatment of cancer, such as, for example, cancers in which agents that target the spliceosome and mutations therein are known to be useful.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562257088P | 2015-11-18 | 2015-11-18 | |
| PCT/US2016/062525 WO2017087667A1 (en) | 2015-11-18 | 2016-11-17 | A solid state form of pladienolide pyridine compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018006155A true MX2018006155A (en) | 2018-08-01 |
Family
ID=57472076
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018006155A MX2018006155A (en) | 2015-11-18 | 2016-11-17 | A solid state form of pladienolide pyridine compounds and methods of use. |
| MX2021001441A MX2021001441A (en) | 2015-11-18 | 2016-11-17 | A solid state form of pladienolide pyridine compounds and methods of use. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021001441A MX2021001441A (en) | 2015-11-18 | 2016-11-17 | A solid state form of pladienolide pyridine compounds and methods of use. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10745387B2 (en) |
| EP (1) | EP3377485B1 (en) |
| JP (2) | JP6312282B2 (en) |
| KR (1) | KR20180083376A (en) |
| CN (1) | CN108473479B (en) |
| AU (2) | AU2016357433B2 (en) |
| BR (1) | BR112018009995B1 (en) |
| CA (1) | CA3004623C (en) |
| ES (1) | ES2757174T3 (en) |
| IL (1) | IL259198B2 (en) |
| MD (1) | MD3377485T2 (en) |
| MX (2) | MX2018006155A (en) |
| RU (2) | RU2743349C2 (en) |
| SG (2) | SG10201913045PA (en) |
| WO (1) | WO2017087667A1 (en) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7335265B2 (en) * | 2018-04-09 | 2023-08-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Certain pladienolide compounds and methods of use |
| CN112368270B (en) | 2018-04-12 | 2023-10-13 | 卫材R&D管理有限公司 | Pladienolide derivatives as spliceosome targeting agents for the treatment of cancer |
| BR112020024551A2 (en) * | 2018-06-01 | 2021-03-02 | Eisai R&D Management Co., Ltd. | methods for using splicing modulators |
| EP4069844A4 (en) * | 2019-12-04 | 2024-03-20 | Pai, Athma A. | Anti-slc6a1 oligonucleotides and related methods |
| TW202233187A (en) | 2020-11-04 | 2022-09-01 | 日商衛材R&D企管股份有限公司 | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
| WO2023131866A1 (en) | 2022-01-05 | 2023-07-13 | Eisai R&D Management Co., Ltd. | Biomarkers for myelodysplastic syndrome (mds) and methods of using the same |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI312681B (en) | 2001-02-01 | 2009-08-01 | Novel physiologically active substance | |
| TWI334866B (en) | 2002-05-29 | 2010-12-21 | Mercian Corp | Novel physiologically active substances |
| AU2003252445B2 (en) | 2002-07-31 | 2009-09-17 | Eisai R & D Management Co., Ltd. | Novel physiologically active substances |
| US7576204B2 (en) | 2002-07-31 | 2009-08-18 | Mercian Corporation | Heterocyclic macrolide pharmaceutical agent, a method of producing the same and use of the same |
| AU2003285012A1 (en) | 2002-10-24 | 2004-05-13 | Sepracor, Inc. | Compositions comprising zopiclone derivatives and methods of making and using the same |
| CA2507641A1 (en) | 2002-11-29 | 2004-06-17 | Mercian Corporation | Method of producing macrolide compound |
| KR20060110865A (en) | 2003-11-27 | 2006-10-25 | 에자이 가부시키가이샤 | Dna participating in hydroxylation of macrolide compound |
| ES2345493T3 (en) | 2003-11-28 | 2010-09-24 | Kanagawa Academy Of Science And Technology | METHOD OF DETECTION OF CANCER OF LIVER, DIAGNOSIS OF CANCER OF LIVER AND REMEDY FOR CANCER. |
| US20070199741A1 (en) | 2004-07-02 | 2007-08-30 | Kenji Noumi | Combined Weighing Apparatus |
| US8008049B2 (en) | 2004-07-20 | 2011-08-30 | Eisai R&D Management Co., Ltd. | DNA coding for polypeptide participating in biosynthesis of pladienolide |
| TW200716744A (en) | 2005-05-26 | 2007-05-01 | Eisai R&D Man Co Ltd | Genetically modified microorganism and process for production of macrolide compound using the microorganism |
| JPWO2007043621A1 (en) | 2005-10-13 | 2009-04-16 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Total Synthesis Method for Pradienolide B and Pradienolide D |
| JPWO2008111464A1 (en) * | 2007-03-05 | 2010-06-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Anticancer drug action test method using splicing abnormality as an index |
| US20080312317A1 (en) | 2007-04-12 | 2008-12-18 | Eisai R&D Management Co., Ltd. | 12 membered-ring macrolactam derivatives |
| UA119458C2 (en) | 2014-05-15 | 2019-06-25 | Ейсей Р Енд Д Менеджмент Ко., Лтд. | Pladienolide pyridine compounds and methods of use |
-
2016
- 2016-11-17 MD MDE20180923T patent/MD3377485T2/en unknown
- 2016-11-17 JP JP2017528992A patent/JP6312282B2/en active Active
- 2016-11-17 MX MX2018006155A patent/MX2018006155A/en unknown
- 2016-11-17 RU RU2018121610A patent/RU2743349C2/en active
- 2016-11-17 AU AU2016357433A patent/AU2016357433B2/en active Active
- 2016-11-17 CN CN201680067749.5A patent/CN108473479B/en active Active
- 2016-11-17 WO PCT/US2016/062525 patent/WO2017087667A1/en active Application Filing
- 2016-11-17 ES ES16805664T patent/ES2757174T3/en active Active
- 2016-11-17 MX MX2021001441A patent/MX2021001441A/en unknown
- 2016-11-17 CA CA3004623A patent/CA3004623C/en active Active
- 2016-11-17 EP EP16805664.6A patent/EP3377485B1/en active Active
- 2016-11-17 SG SG10201913045PA patent/SG10201913045PA/en unknown
- 2016-11-17 US US15/529,798 patent/US10745387B2/en active Active
- 2016-11-17 IL IL259198A patent/IL259198B2/en unknown
- 2016-11-17 KR KR1020187016598A patent/KR20180083376A/en not_active Application Discontinuation
- 2016-11-17 SG SG11201803519YA patent/SG11201803519YA/en unknown
- 2016-11-17 RU RU2021102393A patent/RU2021102393A/en unknown
- 2016-11-17 BR BR112018009995-3A patent/BR112018009995B1/en active IP Right Grant
-
2018
- 2018-03-16 JP JP2018049098A patent/JP6353620B1/en active Active
-
2020
- 2020-07-17 US US16/932,627 patent/US20200361915A1/en not_active Abandoned
-
2021
- 2021-02-15 AU AU2021200974A patent/AU2021200974B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL264034A (en) | Crispr/cas9-based compositions and methods for treating cancer | |
| PH12016502249A1 (en) | Pladienolide pyridine compounds and methods of use | |
| PH12018502535A1 (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| PH12017501483A1 (en) | Bicyclic heterocycles as fgfr4 inhibitors | |
| WO2018112365A3 (en) | Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii | |
| MX2018006155A (en) | A solid state form of pladienolide pyridine compounds and methods of use. | |
| MX2016002544A (en) | Compounds useful as immunomodulators. | |
| TW201613648A (en) | Compounds and compositions for immunotherapy | |
| EP3377516A4 (en) | Methods and compositions for treating cancer | |
| IL272844A (en) | Compounds, compositions and methods for treating or preventing her-driven drug-resistant cancers | |
| MX2016010216A (en) | Solid pharmaceutical compositions of androgen receptor antagonists. | |
| EP3348276A4 (en) | Cancer treatment composition combining anti-cd26 antibody and other anticancer agent | |
| MX2019013808A (en) | Compounds for treatment of cancer. | |
| MX2018000715A (en) | Methods for treating cancer using apilimod. | |
| MX2016009590A (en) | Apilimod compositions and methods for using same. | |
| MX2022006304A (en) | Compositions and methods for inhibiting the biological activity of soluble biomolecules. | |
| WO2019023315A3 (en) | Rac inhibitors | |
| MX368063B (en) | Functionalised benzopyran compounds and use thereof. | |
| MX2017006026A (en) | Apilimod for use in the treatment of colorectal cancer. | |
| MY180844A (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
| PH12016501838A1 (en) | Compounds and their methods of use | |
| EP3298141A4 (en) | Compositions and methods for treating cancer | |
| EP3294301A4 (en) | Compounds and compositions useful for treating or preventing cancer metastasis, and methods using same | |
| EP3268028A4 (en) | Compositions and methods for treating cancer | |
| EP3322484A4 (en) | Compositions and methods for treating cancer |